Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
Maria Gonzalez Calvet and Ryan Rohlfsen to Speak at ACI's 42nd Annual FCPA Conference
BOSTON, Massachusetts, Dec. 3 [Category: BizLaw/Legal] -- Ropes and Gray, a law firm, issued the following news:
* * *
Maria Gonzalez Calvet and Ryan Rohlfsen to Speak at ACI's 42nd Annual FCPA Conference
*
Maria Gonzalez Calvet and Ryan Rohlfsen, co-chairs of the anti-corruption and international risk practice and former members of the U.S. Department of Justice's specialized Foreign Corrupt Practices Act (FCPA) Unit, will speak at the American Conference Institute's (ACI) 42nd Annual Conference on the Foreign Corrupt Practices Act and Global Anti-Corruption.
During the conference, which
... Show Full Article
BOSTON, Massachusetts, Dec. 3 [Category: BizLaw/Legal] -- Ropes and Gray, a law firm, issued the following news:
* * *
Maria Gonzalez Calvet and Ryan Rohlfsen to Speak at ACI's 42nd Annual FCPA Conference
*
Maria Gonzalez Calvet and Ryan Rohlfsen, co-chairs of the anti-corruption and international risk practice and former members of the U.S. Department of Justice's specialized Foreign Corrupt Practices Act (FCPA) Unit, will speak at the American Conference Institute's (ACI) 42nd Annual Conference on the Foreign Corrupt Practices Act and Global Anti-Corruption.
During the conference, whichwill be held December 3-4 in Washington, D.C., Maria will participate in the panel discussion "Managing in Latin America: A Look at the Biggest Ways Cartels/TCOs Are Infiltrating Businesses and Supply Chains, and How Companies Are Responding." This session will examine the top areas of potential cartel infiltration and offer actionable guidance for identifying red flags, protecting supply chains, and strengthening controls across third-party relationships, logistics networks, and procurement processes.
Ryan will participate in a spotlight session with representatives from the United Kingdom's Serious Fraud Office (SFO), France's Parquet National Financier (PNF), and the Swiss Office of the Attorney General (OAG), offering an in-depth look at the latest initiatives of the international anti-corruption prosecutorial task force.
With new U.S. Department of Justice guidance and intensifying global enforcement, ACI's redesigned 2025 program will convene more than 700 members of the global FCPA community for practical, forward-looking insights.
***
Original text here: https://www.ropesgray.com/en/news-and-events/events/2025/12/maria-gonzalez-calvet-and-ryan-rohlfsen-to-speak-at-acis-42nd-annual-fcpa-conference
Oracle Health Secures TEFCA QHIN Designation, Further Strengthening Interoperability Leadership
REDWOOD SHORES, California, Nov. 30 [Category: BizComputer Technology] -- Oracle, a developer of hardware and software products, posted the following news release:
* * *
Oracle Health Secures TEFCA QHIN Designation, Further Strengthening Interoperability Leadership
*
Oracle Health Information Network Inc., a subsidiary of Oracle, has been designated as a Qualified Health Information Network (r) (QHIN(tm)) as a part of the Trusted Exchange Framework and Common Agreement(tm) (TEFCA(tm)). Building on a long legacy of paving the way for interoperability across the healthcare industry, Oracle Health
... Show Full Article
REDWOOD SHORES, California, Nov. 30 [Category: BizComputer Technology] -- Oracle, a developer of hardware and software products, posted the following news release:
* * *
Oracle Health Secures TEFCA QHIN Designation, Further Strengthening Interoperability Leadership
*
Oracle Health Information Network Inc., a subsidiary of Oracle, has been designated as a Qualified Health Information Network (r) (QHIN(tm)) as a part of the Trusted Exchange Framework and Common Agreement(tm) (TEFCA(tm)). Building on a long legacy of paving the way for interoperability across the healthcare industry, Oracle Healthremains at the forefront by participating in the nationwide approach to offer secure, smooth, and standardized sharing of health information across all Designated QHINs and between providers, payers, and government agencies. The Oracle Health Information Network is another offering in Oracle's portfolio to help simplify interoperability for providers.
Earlier this year, Oracle also pledged support for the Centers for Medicare and Medicaid Services' Digital Health Ecosystem and Interoperability Framework.
Oracle Health's hospital and health system customers now have a single point of connectivity for the broader healthcare ecosystem, removing the need to participate in multiple exchange networks to create a consolidated and comprehensive view of the patient.
"Becoming a Designated QHIN marks another milestone in Oracle's commitment and investment to enable safe and secure interoperability that puts patients first," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "We believe data interoperability isn't a technical goal; it's the key to unlocking the solution to many problems in healthcare, from harnessing the power of AI, improving quality of care and health outcomes, and scaling value-based care. Oracle Health Information Network helps offer this foundation to empower providers, public health officials, patients, and payers with secure data access to enhance care delivery, gain valuable insights into community health, and streamline authorizations and reimbursements."
Oracle Health Information Network is powered by Oracle Cloud Infrastructure (OCI) and benefits from its scalability, reliability, advanced security, and high performance, and supports faster and more efficient health data sharing by reducing the dependencies on third party technology that can complicate and slow down the process. Oracle Health customers can participate for free and sign up now by opting in to the Oracle Health Information Network Terms of Participation through Oracle Health Connection Hub. It does not require additional setup, configuration, or consulting engagements.
Oracle Health Information Network delivers a holistic view of the patient by combining data from multiple care venues to drive more informed care decisions and reduce expensive, duplicative testing and clinical processes. The solution can also be used in conjunction with Oracle Health Seamless Exchange, which aggregates data from multiple sources then cleanses and deduplicates the data and integrates it into the Oracle Health Foundation electronic health record (EHR) and next-generation Oracle Health EHR. It significantly reduces time-consuming data review and manual data normalization while increasing data integrity. In addition, customers can use Oracle Health Connection Hub to manage their interoperability services, including the Oracle Health Information Network, to enable interoperability governance, auditing, and access reporting.
"We welcome Oracle Health Information Network as the latest Designated QHIN and are excited to extend the benefits of seamless health information exchange to more participants than ever," said Mariann Yeager, CEO of The Sequoia Project and TEFCA Recognized Coordinating Entity(r) (RCE(r)) Lead.
Additional Resources Regarding Oracle's Commitment to Interoperability
* Oracle Health Information Network's QHIN Frequently Asked Questions
* Learn more about Oracle Health's Interoperable Solutions
* Learn more about TEFCA
***
Original text here: https://www.oracle.com/news/announcement/oracle-health-secures-tefca-qhin-designation-2025-11-20/
GE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025
CHICAGO, Illinois, Nov. 30 [Category: Health Care] -- G.E. HealthCare posted the following news release:
* * *
GE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025
*
* The company will showcase a wave of transformative innovations designed to address the most pressing challenges in healthcare, spanning the care journey across smart devices and drugs throughout disease states enabled by cloud and AI solutions.
* GE HealthCare has invested more than $3B in R&D since 2022, delivering an innovation renaissance across disease states to advance precision
... Show Full Article
CHICAGO, Illinois, Nov. 30 [Category: Health Care] -- G.E. HealthCare posted the following news release:
* * *
GE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025
*
* The company will showcase a wave of transformative innovations designed to address the most pressing challenges in healthcare, spanning the care journey across smart devices and drugs throughout disease states enabled by cloud and AI solutions.
* GE HealthCare has invested more than $3B in R&D since 2022, delivering an innovation renaissance across disease states to advance precisioncare.
CHICAGO Nov. 30, 2025 At this year's Radiological Society of North America's (RSNA) 2025 Annual Meeting, GE HealthCare (Nasdaq: GEHC) will showcase a wave of significant innovations grounded by its legacy and deep, global commitment to advancing precision care. For more than a century, GE HealthCare has stood at the intersection of medicine and technologyhelping clinicians see more, understand more, and do more for their patients. What began with some of the world's earliest technology innovations in medical imaging has evolved into a strong, global focus to advancing precision care.
Solving industry challenges
Radiology departments worldwide are facing unprecedented pressure. In the coming years, healthcare providers are expected to encounter several critical challenges, including a shortage of qualified staff, rising demand for imaging services, rapid technological advancements, and the urgent need to improve operational efficiency across care settings. [1] Amid these challenges, GE HealthCare is developing cloud-based and AI-enabled innovations aimed at helping providers and clinicians turn data into actionable insights, deliver precise diagnoses and treatment plans faster than before, and help hospitals boost their efficiency.
At RSNA 2025, GE HealthCare will showcase more than 40 technology innovations that merge state-of-the-art imaging device technology with advanced digital, computational and AI capabilities and are designed to address these challenges head-on: from AI-enabled imaging systems that are designed to reduce cognitive load and automate routine tasks, to structured reporting tools that can streamline workflows and improve data consistency.
"As we shape the future of care, our commitment remains clear: to deliver transformative technologies that empower clinicians, drive efficiencies, and help improve patient outcomes across multiple care pathways," said Peter Arduini, CEO of GE HealthCare. "We start by listening to our customers, and work backwards from their challenges, then develop truly differentiated products and solutions to meet their needs today and into the future."
Key products driving GE HealthCare's innovation renaissance
GE HealthCare is delivering bold new solutions designed to elevate patient care and enhance the clinician experience. Since 2022, GE HealthCare has invested more than $3 billion in research and development, fueling a wave of innovation across equipment, radiopharmaceuticals and cloud and AI-enabled solutions. This year at RSNA, GE HealthCare will demonstrate new and recently announced innovations, including:
* Photonova(tm) Spectra (510(k) pending with the U.S. FDA; not available for sale) [2] : The new photon counting CT (PCCT) system with advanced AI algorithms, [3] marks a major milestone in the company's decades-long history in CT innovation. Built on GE HealthCare's proprietary Deep Silicon detector technology, Photonova Spectra is designed to deliver remarkable spectral and spatial resolution for ultra-high-definition (UHD) imaging with wide coverage, seeking to enable fast acquisition speeds, precise visualization of anatomical structures and enhanced material separation. This system is designed to maximize the vast amounts of data provided, harnessing up to 50 times more data than conventional CT [4] to enable advanced reconstruction techniques and precise outputs with the aim of supporting enhanced clinical decision-making and smooth workflows.
* N ext-gen SIGNA MRI technology (510(k) pending at the U.S FDA; not available for sale): These technologies are designed to enhance precision diagnosis for clinicians. The innovations include:
* SIGNA(tm) Bolt [5] aims to bring to market our most advanced high-field, clinical wide bore 3.0T MRI system and is seeking to combine ultra-high gradient performance, intelligent digital RF architecture, and sustainable design to deliver precision imaging, fast workflows, and seamless clinical-to-research flexibility, all with exceptionally low energy consumption and operational costs.
* SIGNA(tm) Sprint with Freelium(tm) [6] aims to broaden access to sustainable and equitable MRI technology. With less than 1% helium usage compared to conventional magnets, Freelium is designed to provide effortless sustainability without compromising clinical and operational efficiency.
* Both are powered by SIGNA(tm) One [7], an AI-powered workflow platform designed to improve the imaging experience by combining precision with simplicity.
* Pristina(tm) Recon DL: This solution is GE HealthCare's advanced 3D mammography reconstruction technologythe first to combine deep learning with iterative reconstruction to provide outstanding digital breast tomosynthesis (DBT) image quality at a low patient radiation dose. Pristina Recon DL is an enhancement to GE HealthCare's Pristina Via(tm) system. Pristina Via with Recon DL mammography system offers high clinical confidence and efficient workflows with exceptional patient experience.
* Vivid(tm) Pioneer: GE HealthCare's most advanced and adaptive cardiovascular ultrasound platform. With one-click optimization, AI automation tools, simplified user interface and a lighter, compact, battery supported system, Vivid Pioneer is designed for extraordinary imaging, workflow, and comfort.
* Flyrcado(tm) (flurpiridaz F 18) injection: FDA-approved PET MPI agent for adult patients with known or suspected coronary artery disease to evaluate myocardial ischemia and infarction; higher diagnostic efficacy versus SPECT, exercise-stress PET enabled by a longer half-life, and ready-to-use unit dose to support adoption. Flyrcado is expected to reach a substantial number of cardiac PET centers in the U.S. as adoption continues. CMS traditional pass-through status (effective Apr 1, 2025) supports access in HOPD settings. U.S. audiences only.
* Definium Pace Select ET: An advanced floor-mounted digital X-ray system designed to deliver high-image quality and optimize efficiency in highly demanding environments while enhancing access and affordability. The system solves for many technologist challenges today by automating manual, repetitive steps and helping to reducing physical strain. The system leverages AI to help ensure accurate patient positioning and consistent image quality across various clinical conditions while streamlining the technologist workflow to maximize the patient experience and throughput.
GE HealthCare is at the forefront of developing advanced AI- and cloud-enabled capabilities to help improve workflow efficiency for radiologists. Key highlights this year include:
* Genesis(tm) Radiology Workspace [8] anchored by Genesis Viewer (510(k) pending at the U.S FDA; not available for sale): [9] Software that is designed to be an ultra-fast diagnostic, zero-footprint viewer - streamlining radiology workflows and aiming to enhance patient care while being fully accessible from any location. Genesis Viewer is part of the GE HealthCare's Genesis(tm) Radiology Workspace to help radiologists streamline their workflows. The next-generation solution is designed to transform radiology workflows, unify the user experience, and empower radiologists with great efficiency and precision.
* 100 FDA-authorized AI-enabled solutions: GE HealthCare leads the industry in artificial intelligence innovation, topping the FDA's list for the most AI-enabled device authorizations of any medical device company this year. These solutions are helping to transform clinical workflows, supporting fast and precise decision-making, and expanding access to high-quality care.
"For more than 125 years, GE HealthCare has pioneered technologies that transform patient care. And while we celebrate our heritage, we remain focused on what lies ahead: a future where care is more personalized, connected, and intelligent than ever before," said Roland Rott, CEO and President of Imaging at GE HealthCare. "This year at RSNA, our new innovations continue that tradition, empowering clinicians and advancing the boundaries of what's possible in healthcare."
A legacy rooted in discovery
GE HealthCare has been shaping the future of healthcare for more than a century. From the invention of the first x-ray tube still in use in modern day imaging equipment to today's innovation renaissance, its led advances that redefine diagnostic imaging and how clinicians treat and care for patients. The company's presence at every RSNA since its inception in 1914 reflects an enduring commitment to advance radiology and support the imaging community.
This year, GE HealthCare commemorates a series of transformative achievements that have shaped the landscape of medical imaging and patient care:
* Sixty years of mammography: Since 1965, GE HealthCare has led mammography innovationfrom developing the first dedicated X-ray machine to digital, 3D, and AI-powered technologies that enable early accurate diagnoses. This ongoing commitment to women's health empowers clinicians and aims to improve outcomes worldwide.
* Twenty-five years of PET/CT: Since introducing the world's first commercially available PET/CT system in 2001an innovation that would redefine diagnostic imaging and help transform patient careGE HealthCare has expanded access and helped elevate precision medicine across care pathways. By combining functional and anatomical imaging, PET/CT has become an essential tool for clinicians, helping them detect, stage, and monitor cancer with greater accuracy and confidence.
* A legacy of industry firsts: GE HealthCare's history is marked by groundbreaking achievements, including the development of the first full body CT scanner, the commercialization of magnetic resonance imaging (MR), the introduction of the first color pocket-size handheld ultrasound, Vscan, in 2010, and Flyrcado in 2024, a first-of-its kind PET molecular imaging agent for diagnosing and assessing coronary artery disease, a significant game-changing innovation for nuclear cardiology. Each innovation is designed to set new standards for patient care and clinical excellence.
Strategic collaborations driving innovation
GE HealthCare's commitment to advancing patient care goes beyond research and developmentit's strengthened by strategic collaborations and acquisitions that accelerate innovation. In the past year, the company has strengthened its portfolio to include:
* MIM Software, which enhances GE HealthCare's ability to provide advanced imaging analytics, visualization, and workflow solutions
* Spectronic Medical, delivering innovations that aim to enhance radiation oncology planning
* icometrix, which further expands GE HealthCare's leadership in AI-enabled precision imaging, facilitating neurological disorder diagnosis and monitoring of disease progression
For more information on GE HealthCare and these innovative solutions at RSNA, visit booth 7334, explore the press kit, or the RSNA 2025 events page.
Important Safety Information and Usage of Flyrcado(tm) (flurpiridaz F 18) injection
Indications and Usage
FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.
Contraindications
None
Warnings and Precautions
* Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent's prescribing information.
* Radiation risks: FLYRCADO contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void.
Adverse Reactions
* Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence >= 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia.
Use in Specific Populations
* Pregnancy
* There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure.
* FLYRCADO contains ethanol (a maximum daily dose of 337 mg anhydrous ethanol). If considering FLYRCADO administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes associated with ethanol exposure during pregnancy.
* Lactation
* Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO administration.
* Pediatric Use
* Safety and effectiveness of FLYRCADO in pediatric patients have not been established.
To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at GPV.drugsafety@gehealthcare.com or FDA at 800-FDA-1088 or www.fda.gov/medwatch
For full prescribing information, click here. For important safety information, please click here.
[1] Elizabeth H. Dibble et al. "Workforce Shortage and Strategies for Mitigation: Results from the 2022 ACR/Radiology Business Management Association Workforce Survey." Journal of the American College of Radiology 22, no. 5 (2025): 573-576. https://doi.org/10.1016/j.jacr.2025.01.xxx.
[2] Photonova Spectra is 510(k)-pending with the U.S. FDA. Not CE Marked. Not available for sale in the United States, Europe, Canada, or any other region.
[3] Enhanced Boundary for PCCT is 510(k)-pending with the U.S. FDA. Not CE Marked. Not available for sale in the United States, Europe, Canada, or any other region.
[4] When compared to Revolution Apex Elite.
[5] SIGNA Bolt is 510(k) pending at U.S. FDA. Not CE marked. Not available for sale.
[6] SIGNA Sprint with Freelium is a sealed configuration of SIGNA Sprint Select. SIGNA Sprint Select is 510(k) pending at U.S. FDA. Not CE marked. Not available for sale.
[7] SIGNA One is 510(k) pending with the U.S. FDA. Not CE marked. Not available for sale.
[8] Genesis Radiology Workspace consists of Genesis View, Enterprise Archive, Workflow Manager and App Orchestrator.
[9] Genesis Viewer is 510(k) Pending at the U.S. FDA; not available for sale.
***
Original text here: https://www.gehealthcare.com/about/newsroom/press-releases/ge-healthcare-builds-on-a-century-of-innovation-to-shape-the-future-of-radiology-at-rsna-2025
UPDATE: ZOE SALDANA, GILLIAN ANDERSON, JOHN CENA, MILEY CYRUS AND MORE GUESTS ON ABC'S 'JIMMY KIMMEL LIVE,' DEC. 1-5
BURBANK, California, Nov. 29 [Category: BizArts/Cultural] -- ABC, a division of Walt Disney, posted the following news release:
* * *
UPDATE: ZOE SALDANA, GILLIAN ANDERSON, JOHN CENA, MILEY CYRUS AND MORE GUESTS ON ABC'S 'JIMMY KIMMEL LIVE,' DEC. 1-5
*
ABC's Emmy(r) Award-winning late-night talk show, "Jimmy Kimmel Live," airs every weeknight at 11:35 p.m. EST and features a diverse lineup of guests that includes celebrities, athletes, musical acts, comedians and human-interest subjects, along with comedy bits and a house band.
The following episodes are scheduled to air the week of Dec.
... Show Full Article
BURBANK, California, Nov. 29 [Category: BizArts/Cultural] -- ABC, a division of Walt Disney, posted the following news release:
* * *
UPDATE: ZOE SALDANA, GILLIAN ANDERSON, JOHN CENA, MILEY CYRUS AND MORE GUESTS ON ABC'S 'JIMMY KIMMEL LIVE,' DEC. 1-5
*
ABC's Emmy(r) Award-winning late-night talk show, "Jimmy Kimmel Live," airs every weeknight at 11:35 p.m. EST and features a diverse lineup of guests that includes celebrities, athletes, musical acts, comedians and human-interest subjects, along with comedy bits and a house band.
The following episodes are scheduled to air the week of Dec.1-5 (subject to change):
Monday, Dec. 1
1\. Zoe Saldana ("Avatar: Fire and Ash") 2. Paul Anka ("Paul Anka: His Way" and "Inspirations of Life and Love") 3. Musical Guest Paul Anka
Tuesday, Dec. 2
1\. Gillian Anderson ("The Abandons") 2. Kevin Nealon ("Take A Hike" campaign with the Appalachian Trail Conservancy) 3. Musical Guest Jack Johnson featuring Hermanos Gutierrez
Wednesday, Dec. 3
1\. John Cena ("WWE | John Cena's Last RAW") 2. Druski ("Coulda Fest" Tour) 3. Musical Guest Silvana Estrada
Thursday, Dec. 4
1\. Miley Cyrus ("Dream As One" from "Avatar: Fire and Ash") 2. Cameron Crowe ("The Uncool") 3. Musical Guest Rufus Wainwright
Friday, Dec. 5
TBC
Media Contacts
You must be logged in to view this content. Please log in or create an account.
***
Original text here: https://www.detpress.com/abc/pressrelease/update-zoe-saldana-gillian-anderson-john-cena-miley-cyrus-and-more-guests-on-abcs-jimmy-kimmel-live-dec-1-5/
Oracle Health Secures TEFCA QHIN Designation, Further Strengthening Interoperability Leadership
REDWOOD SHORES, California, Nov. 29 [Category: BizComputer Technology] -- Oracle, a developer of hardware and software products, posted the following news release:
* * *
Oracle Health Secures TEFCA QHIN Designation, Further Strengthening Interoperability Leadership
*
Oracle Health Information Network Inc., a subsidiary of Oracle, has been designated as a Qualified Health Information Network (r) (QHIN(tm)) as a part of the Trusted Exchange Framework and Common Agreement(tm) (TEFCA(tm)). Building on a long legacy of paving the way for interoperability across the healthcare industry, Oracle Health
... Show Full Article
REDWOOD SHORES, California, Nov. 29 [Category: BizComputer Technology] -- Oracle, a developer of hardware and software products, posted the following news release:
* * *
Oracle Health Secures TEFCA QHIN Designation, Further Strengthening Interoperability Leadership
*
Oracle Health Information Network Inc., a subsidiary of Oracle, has been designated as a Qualified Health Information Network (r) (QHIN(tm)) as a part of the Trusted Exchange Framework and Common Agreement(tm) (TEFCA(tm)). Building on a long legacy of paving the way for interoperability across the healthcare industry, Oracle Healthremains at the forefront by participating in the nationwide approach to offer secure, smooth, and standardized sharing of health information across all Designated QHINs and between providers, payers, and government agencies. The Oracle Health Information Network is another offering in Oracle's portfolio to help simplify interoperability for providers.
Earlier this year, Oracle also pledged support for the Centers for Medicare and Medicaid Services' Digital Health Ecosystem and Interoperability Framework.
Oracle Health's hospital and health system customers now have a single point of connectivity for the broader healthcare ecosystem, removing the need to participate in multiple exchange networks to create a consolidated and comprehensive view of the patient.
"Becoming a Designated QHIN marks another milestone in Oracle's commitment and investment to enable safe and secure interoperability that puts patients first," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "We believe data interoperability isn't a technical goal; it's the key to unlocking the solution to many problems in healthcare, from harnessing the power of AI, improving quality of care and health outcomes, and scaling value-based care. Oracle Health Information Network helps offer this foundation to empower providers, public health officials, patients, and payers with secure data access to enhance care delivery, gain valuable insights into community health, and streamline authorizations and reimbursements."
Oracle Health Information Network is powered by Oracle Cloud Infrastructure (OCI) and benefits from its scalability, reliability, advanced security, and high performance, and supports faster and more efficient health data sharing by reducing the dependencies on third party technology that can complicate and slow down the process. Oracle Health customers can participate for free and sign up now by opting in to the Oracle Health Information Network Terms of Participation through Oracle Health Connection Hub. It does not require additional setup, configuration, or consulting engagements.
Oracle Health Information Network delivers a holistic view of the patient by combining data from multiple care venues to drive more informed care decisions and reduce expensive, duplicative testing and clinical processes. The solution can also be used in conjunction with Oracle Health Seamless Exchange, which aggregates data from multiple sources then cleanses and deduplicates the data and integrates it into the Oracle Health Foundation electronic health record (EHR) and next-generation Oracle Health EHR. It significantly reduces time-consuming data review and manual data normalization while increasing data integrity. In addition, customers can use Oracle Health Connection Hub to manage their interoperability services, including the Oracle Health Information Network, to enable interoperability governance, auditing, and access reporting.
"We welcome Oracle Health Information Network as the latest Designated QHIN and are excited to extend the benefits of seamless health information exchange to more participants than ever," said Mariann Yeager, CEO of The Sequoia Project and TEFCA Recognized Coordinating Entity(r) (RCE(r)) Lead.
Additional Resources Regarding Oracle's Commitment to Interoperability
* Oracle Health Information Network's QHIN Frequently Asked Questions
* Learn more about Oracle Health's Interoperable Solutions
* Learn more about TEFCA
***
Original text here: https://www.oracle.com/news/announcement/oracle-health-secures-tefca-qhin-designation-2025-11-20/
Oracle Health Secures TEFCA QHIN Designation, Further Strengthening Interoperability Leadership
REDWOOD SHORES, California, Nov. 28 [Category: BizComputer Technology] -- Oracle, a developer of hardware and software products, posted the following news release:
* * *
Oracle Health Secures TEFCA QHIN Designation, Further Strengthening Interoperability Leadership
*
Oracle Health Information Network Inc., a subsidiary of Oracle, has been designated as a Qualified Health Information Network (r) (QHIN(tm)) as a part of the Trusted Exchange Framework and Common Agreement(tm) (TEFCA(tm)). Building on a long legacy of paving the way for interoperability across the healthcare industry, Oracle Health
... Show Full Article
REDWOOD SHORES, California, Nov. 28 [Category: BizComputer Technology] -- Oracle, a developer of hardware and software products, posted the following news release:
* * *
Oracle Health Secures TEFCA QHIN Designation, Further Strengthening Interoperability Leadership
*
Oracle Health Information Network Inc., a subsidiary of Oracle, has been designated as a Qualified Health Information Network (r) (QHIN(tm)) as a part of the Trusted Exchange Framework and Common Agreement(tm) (TEFCA(tm)). Building on a long legacy of paving the way for interoperability across the healthcare industry, Oracle Healthremains at the forefront by participating in the nationwide approach to offer secure, smooth, and standardized sharing of health information across all Designated QHINs and between providers, payers, and government agencies. The Oracle Health Information Network is another offering in Oracle's portfolio to help simplify interoperability for providers.
Earlier this year, Oracle also pledged support for the Centers for Medicare and Medicaid Services' Digital Health Ecosystem and Interoperability Framework.
Oracle Health's hospital and health system customers now have a single point of connectivity for the broader healthcare ecosystem, removing the need to participate in multiple exchange networks to create a consolidated and comprehensive view of the patient.
"Becoming a Designated QHIN marks another milestone in Oracle's commitment and investment to enable safe and secure interoperability that puts patients first," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "We believe data interoperability isn't a technical goal; it's the key to unlocking the solution to many problems in healthcare, from harnessing the power of AI, improving quality of care and health outcomes, and scaling value-based care. Oracle Health Information Network helps offer this foundation to empower providers, public health officials, patients, and payers with secure data access to enhance care delivery, gain valuable insights into community health, and streamline authorizations and reimbursements."
Oracle Health Information Network is powered by Oracle Cloud Infrastructure (OCI) and benefits from its scalability, reliability, advanced security, and high performance, and supports faster and more efficient health data sharing by reducing the dependencies on third party technology that can complicate and slow down the process. Oracle Health customers can participate for free and sign up now by opting in to the Oracle Health Information Network Terms of Participation through Oracle Health Connection Hub. It does not require additional setup, configuration, or consulting engagements.
Oracle Health Information Network delivers a holistic view of the patient by combining data from multiple care venues to drive more informed care decisions and reduce expensive, duplicative testing and clinical processes. The solution can also be used in conjunction with Oracle Health Seamless Exchange, which aggregates data from multiple sources then cleanses and deduplicates the data and integrates it into the Oracle Health Foundation electronic health record (EHR) and next-generation Oracle Health EHR. It significantly reduces time-consuming data review and manual data normalization while increasing data integrity. In addition, customers can use Oracle Health Connection Hub to manage their interoperability services, including the Oracle Health Information Network, to enable interoperability governance, auditing, and access reporting.
"We welcome Oracle Health Information Network as the latest Designated QHIN and are excited to extend the benefits of seamless health information exchange to more participants than ever," said Mariann Yeager, CEO of The Sequoia Project and TEFCA Recognized Coordinating Entity(r) (RCE(r)) Lead.
Additional Resources Regarding Oracle's Commitment to Interoperability
* Oracle Health Information Network's QHIN Frequently Asked Questions
* Learn more about Oracle Health's Interoperable Solutions
* Learn more about TEFCA
***
Original text here: https://www.oracle.com/news/announcement/oracle-health-secures-tefca-qhin-designation-2025-11-20/
Inflammation and metabolic stress combine to drive a new cell death pathway: mitoxyperilysis
MEMPHIS, Tennessee, Nov. 28 [Category: BizHospital] -- St. Jude Children's Research Hospital issued the following news release:
* * *
Inflammation and metabolic stress combine to drive a new cell death pathway: mitoxyperilysis
*
In several disease conditions, including infections and cancers, innate immune activation and nutrient scarcity occur together. A study from St. Jude Children's Research Hospital published today in Cell found that this combination causes a unique type of cell death, named mitoxyperilysis. The research revealed that mitochondria persist near the cell membrane, causing
... Show Full Article
MEMPHIS, Tennessee, Nov. 28 [Category: BizHospital] -- St. Jude Children's Research Hospital issued the following news release:
* * *
Inflammation and metabolic stress combine to drive a new cell death pathway: mitoxyperilysis
*
In several disease conditions, including infections and cancers, innate immune activation and nutrient scarcity occur together. A study from St. Jude Children's Research Hospital published today in Cell found that this combination causes a unique type of cell death, named mitoxyperilysis. The research revealed that mitochondria persist near the cell membrane, causinglocal oxidative damage that results in the cells self-destructing, regulated by specific inflammatory and metabolic signaling pathways. They also found that this type of cell death can be therapeutically activated in cancer models to regress tumors, highlighting potential implications for cancer treatments.
"We discovered that innate immune and metabolic disruptions led to a synergistic effect activating a new cell death pathway that we characterized as mitoxyperilysis," said corresponding author Thirumala-Devi Kanneganti, PhD, St. Jude Center of Excellence for Innate Immunity and Inflammation director and Department of Immunology vice chair. "Understanding cell death pathways is literally a matter of life and death. We believe that by mechanistically defining this new pathway, we've provided biochemical nodes that can be investigated for future lifesaving therapeutic interventions."
Mitochondria power mitoxyperilysis at the cell membrane
Infections and other diseases, such as cancer, cause molecular alarm signals to be released in the body, activating the innate immune system. At the same time, infected or cancerous cells compete for the nutrients nearby, resulting in metabolic stress in the area. While scientists have studied both processes separately, they are rarely studied together, creating a major gap in our understanding of biological processes that occur in the body. When the researchers observed how the two worked together, they found that many cells went through a previously undescribed kind of inflammatory cell death.
Usually, mitochondria constantly move around in cells and perform their functions to provide energy. If they are damaged, they create reactive oxygen species, a dangerous version of the element oxygen that chemically reacts with nearby structures, causing cellular damage. When the St. Jude scientists combined innate immune activation and nutrient limitation, they found by microscopy that damaged mitochondria move near the cellular membrane. That proximity allowed these reactive oxygen species to assault the membrane until it breaks or "lyses," leading to inflammatory cell death.
"We saw these mitochondria were stuck in contact with the cell membrane for a long period, until the cells burst at the contact sites," said first author Yaqiu Wang, PhD, St. Jude Department of Immunology. "That mechanism is not known as a part of any other cell death pathway, showing mitoxyperilysis is a novel form of cell death."
When the scientists looked for what molecules controlled mitoxyperilysis, they found a well-known metabolic signaling protein, mTOR. If they inhibited or deleted mTOR, cells would pull mitochondria back from the membrane, preventing cell lysis. They also found that both innate immune and metabolic signaling were essential for this process, with genetic evidence showing that deleting the innate immune receptor also prevented cell death.
***
Original text here: https://www.stjude.org/media-resources/news-releases/2025-medicine-science-news/inflammation-and-metabolic-stress-combine-to-drive-new-cell-death-pathway-mitoxyperilysis.html
